vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Rimini Street, Inc. (RMNI). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $105.5M, roughly 1.6× Rimini Street, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
ESPR vs RMNI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $105.5M |
| Net Profit | — | $1.4M |
| Gross Margin | — | 59.0% |
| Operating Margin | 50.6% | 4.6% |
| Net Margin | — | 1.3% |
| Revenue YoY | 143.7% | 1.2% |
| Net Profit YoY | — | -59.4% |
| EPS (diluted) | $0.32 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $105.5M | ||
| Q4 25 | $168.4M | $109.8M | ||
| Q3 25 | $87.3M | $103.4M | ||
| Q2 25 | $82.4M | $104.1M | ||
| Q1 25 | $65.0M | $104.2M | ||
| Q4 24 | $69.1M | $114.2M | ||
| Q3 24 | $51.6M | $104.7M | ||
| Q2 24 | $73.8M | $103.1M |
| Q1 26 | — | $1.4M | ||
| Q4 25 | — | $724.0K | ||
| Q3 25 | $-31.3M | $2.8M | ||
| Q2 25 | $-12.7M | $30.3M | ||
| Q1 25 | $-40.5M | $3.4M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | $-29.5M | $-43.1M | ||
| Q2 24 | $-61.9M | $-1.1M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | — | 60.4% | ||
| Q3 25 | — | 59.9% | ||
| Q2 25 | — | 60.4% | ||
| Q1 25 | — | 61.0% | ||
| Q4 24 | — | 63.7% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | — | 4.6% | ||
| Q4 25 | 50.6% | 4.5% | ||
| Q3 25 | -11.4% | 4.2% | ||
| Q2 25 | 8.6% | 39.6% | ||
| Q1 25 | -34.0% | 9.0% | ||
| Q4 24 | -6.4% | 13.0% | ||
| Q3 24 | -31.0% | -47.4% | ||
| Q2 24 | 3.5% | -0.8% |
| Q1 26 | — | 1.3% | ||
| Q4 25 | — | 0.7% | ||
| Q3 25 | -35.9% | 2.7% | ||
| Q2 25 | -15.4% | 29.1% | ||
| Q1 25 | -62.2% | 3.2% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | -57.2% | -41.2% | ||
| Q2 24 | -83.9% | -1.1% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $0.32 | $0.00 | ||
| Q3 25 | $-0.16 | $0.03 | ||
| Q2 25 | $-0.06 | $0.32 | ||
| Q1 25 | $-0.21 | $0.04 | ||
| Q4 24 | $-0.14 | $0.07 | ||
| Q3 24 | $-0.15 | $-0.47 | ||
| Q2 24 | $-0.33 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $132.2M |
| Total DebtLower is stronger | — | $56.4M |
| Stockholders' EquityBook value | $-302.0M | — |
| Total Assets | $465.9M | $397.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $132.2M | ||
| Q4 25 | $167.9M | $120.0M | ||
| Q3 25 | $92.4M | $108.7M | ||
| Q2 25 | $86.1M | $101.3M | ||
| Q1 25 | $114.6M | $122.6M | ||
| Q4 24 | $144.8M | $88.8M | ||
| Q3 24 | $144.7M | $119.5M | ||
| Q2 24 | $189.3M | $134.2M |
| Q1 26 | — | $56.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-302.0M | $-27.0M | ||
| Q3 25 | $-451.4M | $-27.3M | ||
| Q2 25 | $-433.5M | $-29.0M | ||
| Q1 25 | $-426.2M | $-63.7M | ||
| Q4 24 | $-388.7M | $-69.4M | ||
| Q3 24 | $-370.2M | $-76.8M | ||
| Q2 24 | $-344.2M | $-36.1M |
| Q1 26 | — | $397.1M | ||
| Q4 25 | $465.9M | $423.1M | ||
| Q3 25 | $364.0M | $352.9M | ||
| Q2 25 | $347.1M | $397.5M | ||
| Q1 25 | $324.0M | $343.0M | ||
| Q4 24 | $343.8M | $369.1M | ||
| Q3 24 | $314.1M | $343.8M | ||
| Q2 24 | $352.3M | $367.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $19.6M | ||
| Q3 25 | $-4.3M | $24.7M | ||
| Q2 25 | $-31.4M | $-17.8M | ||
| Q1 25 | $-22.6M | $33.7M | ||
| Q4 24 | $-35.0M | $-37.7M | ||
| Q3 24 | $-35.3M | $-18.5M | ||
| Q2 24 | $-7.2M | $6.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $18.9M | ||
| Q3 25 | — | $23.5M | ||
| Q2 25 | — | $-19.5M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $-38.4M | ||
| Q3 24 | $-35.5M | $-19.2M | ||
| Q2 24 | $-7.3M | $5.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 22.7% | ||
| Q2 25 | — | -18.8% | ||
| Q1 25 | — | 31.5% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | -68.7% | -18.3% | ||
| Q2 24 | -9.9% | 5.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.1% | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 27.02× | ||
| Q3 25 | — | 8.94× | ||
| Q2 25 | — | -0.59× | ||
| Q1 25 | — | 10.06× | ||
| Q4 24 | — | -5.66× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RMNI
Segment breakdown not available.
